Pulse Explore Journal Club Debates Trending Researchers

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

Chronic Ataxic Neuropathy With Disialosyl Antibodies Responsive to Zanubrutinib. | Synapse

February 27, 2026

View Full Paper

Chronic Ataxic Neuropathy With Disialosyl Antibodies Responsive to Zanubrutinib.

Key Points

To explore the effects of zanubrutinib therapy on a patient with Waldenström-associated chronic ataxic neuropathy with disialosyl antibodies.
Case report detailing clinical and therapeutic interventions
Assessment of hematological and neurophysiological outcomes
Patient exhibited significant clinical improvement
Hematological parameters showed positive change after treatment
Neurophysiological assessments indicated enhanced nerve function post-therapy

Abstract

To the best of our knowledge, this is the first patient with Waldenström-associated CANDA with clinical, hematological, and neurophysiological benefit after zanubrutinib therapy.

Ask AI

Helpful

Bookmark

Share

View Full Paper

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Tierro et al. (Sun,) studied this question.

synapsesocial.com/papers/69a1357fed1d949a99abf6cf https://doi.org/https://doi.org/10.1111/ene.70521

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Zanubrutinib Combined With Rituximab in the Treatment of Bing‐Neel Syndrome: A Case Report2025
2Zanubrutinib for high-risk Waldenström macroglobulinemia with complex karyotype and hyperleukocytosis: A case report and literature review2025
3Safety and efficacy of zanubrutinib in waldenstrom macroglobulinemia patients treated in common clinical practice: A retrospective-prospective study by fondazione italiana linfomi (FIL)2025
4Efficacy and safety of zanubrutinib in patients with non-IgM lymphoplasmacytic lymphoma2025
5Efficacy and Safety of Zanubrutinib Combined with Rituximab and High-Dose Methotrexate in the Treatment of Central Nervous System Diffuse Large B-Cell Lymphoma2025